Novartis Venture Fund co-led the gene therapy developer's series A round, raised as it prepares to submit an investigational new drug application for its lead drug.

Renovacor, a US-based gene therapy spinout of Temple University focused on cardiovascular disease, closed an $11m series A round yesterday co-led by Novartis Venture Fund, a corporate venturing subsidiary of pharmaceutical firm Novartis. The round was co-led by venture capital firm BioAdvance and Broadview Ventures, a cardiovascular-focused impact investment vehicle formed by family office Leducq…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.